Abstract
Trastuzumab deruxtecan (T-DXd) is reshaping the therapeutic landscape of HER2-positive tumors. A recent article reports on the preclinical activity of the combination of T-DXd plus adavosertib, WEE1 kinase inhibitor, which promises to expand the use of this antibody-drug conjugate in HER2-positive tumors with CCNE1 coamplification. See related article by DiPeri et al., p. 4385.
©2023 American Association for Cancer Research.
MeSH terms
-
Antibodies, Monoclonal, Humanized / pharmacology
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Breast Neoplasms* / drug therapy
-
Breast Neoplasms* / genetics
-
Camptothecin / pharmacology
-
Camptothecin / therapeutic use
-
Female
-
Humans
-
Immunoconjugates* / pharmacology
-
Immunoconjugates* / therapeutic use
-
Neoplasms* / drug therapy
-
Neoplasms* / genetics
-
Receptor, ErbB-2 / genetics
-
Trastuzumab / therapeutic use
Substances
-
trastuzumab deruxtecan
-
Antibodies, Monoclonal, Humanized
-
Receptor, ErbB-2
-
Trastuzumab
-
Camptothecin
-
Immunoconjugates